Pliant Therapeutics (PLRX) said late Friday it has suspended enrollment and treatment in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis following a recommendation from the trial's data safety monitoring board.
The company said it is analyzing data to better understand the board's reasoning.
"Blinding of the study will be maintained to preserve trial integrity," Pliant Therapeutics said.
The company's shares were down 54% in Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.